Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results